HDAC2 (1-488, His-tag) antigen

Price:

688.93 €

Known as:: HDAC2 (1-488, histidine-detection labelled) antigenic
Catalog number:: 'AR39094PU-N
Product Quantity:: 50
Category:: -
Supplier:: ACR
Gene target:: HDAC2 (1-488 His-tag) antigen

Gene:: DHRS4-AS1 ^{NIH gene}
Name:: DHRS4 antisense RNA 1
Previous symbol:: C14orf167
Synonyms:: PRO1488, AS1DHRS4
Chromosome:: 14q11.2
Locus Type:: RNA, long non-coding
Date approved:: 2003-09-29
Date modifiied:: 2016-12-01

Gene:: DHX36 ^{NIH gene}
Name:: DEAH-box helicase 36
Previous symbol:: DDX36
Synonyms:: MLEL1, KIAA1488, RHAU
Chromosome:: 3q25.2
Locus Type:: gene with protein product
Date approved:: 2001-11-23
Date modifiied:: 2018-07-25

Gene:: HDAC2 ^{NIH gene}
Name:: histone deacetylase 2
Previous symbol:: -
Synonyms:: RPD3, YAF1, KDAC2
Chromosome:: 6q21
Locus Type:: gene with protein product
Date approved:: 1996-11-15
Date modifiied:: 2019-02-19

Gene:: HSH2D ^{NIH gene}
Name:: hematopoietic SH2 domain containing
Previous symbol:: -
Synonyms:: ALX, HSH2, FLJ14886
Chromosome:: 19p13.11
Locus Type:: gene with protein product
Date approved:: 2004-03-31
Date modifiied:: 2016-10-11

Related products to: HDAC2 (1-488, His-tag) antigen

Related articles to: HDAC2 (1-488, His-tag) antigen

Oxyresveratrol-β-cyclodextrin mitigates streptozotocin-induced Alzheimer's model cognitive impairment, histone deacetylase activity in rats: in silico & in vivo studies.
Alzheimer's disease (AD) is associated with cognitive deficits and epigenetic deacetylation that can be modulated by natural products. The role of natural oxyresveratrol-β-cyclodextrin (ORV) on cognition and histone deacetylase activity in AD is unclear. Herein, in-silico docking and molecular dynamics simulation analysis determined that oxyresveratrol potentially targets histone deacetylase-2 (HDAC2). We therefore evaluated the in vivo ameliorative effect of ORV against cognitive deficit, cerebral and hippocampal expression of HDAC in experimental AD rats. Intracerebroventricular injection of STZ (3 mg/kg) induced experimental AD and the rats were treated with low dose (200 mg/kg), high dose (400 mg/kg) of ORV and donepezil (10 mg/kg) for 21 days. The STZ-induced AD caused cognitive and behavioural deficits demonstrated by considerable increases in acetylcholinesterase activity and escape latency compared to sham control. The levels of malondialdehyde (MDA) and HDAC activity were significantly increased in AD disease group comparison to the sham. Interestingly, the ORV reversed the cognitive-behavioural deficit and prominently reduced the MDA and HDAC levels comparable to the effect of the standard drug, donepezil. The findings suggest anti-AD role of ORV via antioxidant effect and inhibition of HDAC in the hippocampal and frontal cortical area of rats for AD. - Source: PubMed
Publication date: 2024/04/30
Agarwal TusharManandhar SumanB Harish KumarFamurewa Ademola CGurram Prasada ChowdariSuggala Ramya ShriSankhe RunaliMudgal JayeshPai K Sreedhara Ranganath
SARS-CoV-2 NSP5 ANTAGONIZES MHC II expression by subverting histone Deacetylase 2.
SARS-CoV-2 interferes with antigen presentation by downregulating MHC II on antigen-presenting cells, but the mechanism mediating this process is unelucidated. Herein, analysis of protein and gene expression in human antigen-presenting cells reveals that MHC II is downregulated by the SARS-CoV-2 main protease, NSP5. This suppression of MHC II expression occurs via decreased expression of the MHC II regulatory protein CIITA. CIITA downregulation is independent of NSP5's proteolytic activity, and rather, NSP5 delivers HDAC2 to IRF3 at an IRF binding site within the CIITA promoter. Here, HDAC2 deacetylates and inactivates the CIITA promoter. This loss of CIITA expression prevents further expression of MHC II, with this suppression alleviated by ectopic expression of CIITA or knockdown of HDAC2. These results identify a mechanism by which SARS-CoV-2 limits MHC II expression, thereby delaying or weakening the subsequent adaptive immune response. - Source: PubMed
Publication date: 2024/04/29
Taefehshokr NimaLac AlexVrieze Angela MDickson Brandon HGuo Peter NJung CatherineBlythe Eoin NFink CorbyAktar AmenaDikeakos Jimmy DDekaban Gregory AHeit Bryan
HDAC1/2 and HDAC3 play distinct roles in controlling adult Meibomian gland homeostasis.
To investigate the roles of HDAC1/2 and HDAC3 in adult Meibomian gland (MG) homeostasis. - Source: PubMed
Publication date: 2024/04/26
Zhu XumingXu MingangMillar Sarah E
Exclusion of HDAC1/2 complexes by oncogenic nuclear condensates.
Nuclear condensates have been shown to regulate cell fate control, but its role in oncogenic transformation remains largely unknown. Here we show acquisition of oncogenic potential by nuclear condensate remodeling. The proto-oncogene SS18 and its oncogenic fusion SS18-SSX1 can both form condensates, but with drastically different properties and impact on 3D genome architecture. The oncogenic condensates, not wild type ones, readily exclude HDAC1 and 2 complexes, thus, allowing aberrant accumulation of H3K27ac on chromatin loci, leading to oncogenic expression of key target genes. These results provide the first case for condensate remodeling as a transforming event to generate oncogene and such condensates can be targeted for therapy. One sentence summary: Expulsion of HDACs complexes leads to oncogenic transformation. - Source: PubMed
Publication date: 2024/04/27
Kuang JunqiLi PengliZhai ZiweiFan YixinXu HuaiYuanZhao ChengchenLi WeiLi XiaoxiLiang ZechuanHuang TaoQin YueGao HuiruMa ZhaoyiLiu DongZhong GuifaWang BoLiu JingWang JinTortorella Micky DLiao BaojianPei Duanqing
Benzothiazole derivatives as histone deacetylase inhibitors for the treatment of autosomal dominant polycystic kidney disease.
Recent evidence suggests that histone deacetylases (HDACs) are important regulators of autosomal dominant polycystic kidney disease (ADPKD). In the present study, a series of benzothiazole-bearing compounds were designed and synthesized as potential HDAC inhibitors. Given the multiple participation of HDACs in ADPKD cyst progression, we embarked on a targeted screen using HeLa nuclear extracts to identify potent pan-HDAC inhibitors. Compound 26 emerged as the most efficacious candidate. Subsequent pharmacological characterization showed that compound 26 effectively inhibits several HDACs, notably HDAC1, HDAC2, and HDAC6 (IC < 150 nM), displaying a particularly high sensitivity towards HDAC6 (IC = 11 nM). The selected compound significantly prevented cyst formation and expansion in an in vitro cyst model and was efficacious in reducing cyst growth in both an embryonic kidney cyst model and an in vivo ADPKD mouse model. Our results provided compelling evidence that compound 26 represents a new HDAC inhibitor for the treatment of ADPKD. - Source: PubMed
Publication date: 2024/04/18
Cao XudongFan ZhiyuanXu LingfangZhao WenchaoZhang HaoranYang YunfangRen YingXiao YuxianZhou NanYin LongZhou XueyanZhu XuGuo Dong

HDAC2 (1-488, His-tag) antigen

Related genes to: HDAC2 (1-488, His-tag) antigen

Related products to: HDAC2 (1-488, His-tag) antigen

Related articles to: HDAC2 (1-488, His-tag) antigen

Oxyresveratrol-β-cyclodextrin mitigates streptozotocin-induced Alzheimer's model cognitive impairment, histone deacetylase activity in rats: in silico & in vivo studies.

SARS-CoV-2 NSP5 ANTAGONIZES MHC II expression by subverting histone Deacetylase 2.

HDAC1/2 and HDAC3 play distinct roles in controlling adult Meibomian gland homeostasis.

Exclusion of HDAC1/2 complexes by oncogenic nuclear condensates.

Benzothiazole derivatives as histone deacetylase inhibitors for the treatment of autosomal dominant polycystic kidney disease.